Wright, Thomas D <br/><br/>
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.  [electronic resource] 

 -  Journal of cellular biochemistry  02 2020 
 - 1156-1168 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-4644 
<br/><br/><label>Standard No.: </label>10.1002/jcb.29350  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Benzodiazepinones--pharmacology<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Drug Synergism<br/>Female<br/>Humans<br/>MAP Kinase Kinase 5--antagonists & inhibitors<br/>Mitogen-Activated Protein Kinase 7--antagonists & inhibitors<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors--pharmacology<br/>Piperazines--pharmacology<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Pyridones--pharmacology<br/>Pyrimidines--pharmacology<br/>Pyrimidinones--pharmacology<br/>Signal Transduction--drug effects<br/>Triple Negative Breast Neoplasms--metabolism